<p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX - 获取免费报告）在目前覆盖该公司的十五位分析师中被评为 “适度买入”，Marketbeat.com 报道。一位投资分析师给予该股票卖出评级，十三位给予买入评级，一位给予强烈买入评级。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价为 12.2308 美元。</p>
<p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<ul>
<li>分析师仍然看好的前三家高动量公司</li>
</ul>
<p>多家券商最近对 CMPX 发表了评论。Lifesci Capital 在 10 月 6 日的报告中开始覆盖 Compass Therapeutics。他们给予该公司 “跑赢大盘” 的评级，并设定了 10.00 美元的目标价。William Blair 在 1 月 5 日的研究报告中开始覆盖 Compass Therapeutics。他们对该股票给予了 “跑赢大盘” 的评级。Compass Point 在 10 月 6 日的报告中对 Compass Therapeutics 设定了 10.00 美元的目标价。Citizens Jmp 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics。他们给予该股票 “市场跑赢大盘” 的评级，并设定了 10.00 美元的目标价。最后，JMP Securities 在 12 月 3 日的研究报告中对 Compass Therapeutics 设定了 10.00 美元的目标。</p>
<p><strong>阅读我们关于 Compass Therapeutics 的最新研究报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>对冲基金最近对该公司的持仓进行了调整。Flagship Harbor Advisors LLC 在第四季度购买了 Compass Therapeutics 的新股份，价值约 32,000 美元。Tema Etfs LLC 在第四季度收购了 Compass Therapeutics 的新股份，价值约 538,000 美元。Avanza Fonder AB 在第四季度购买了 Compass Therapeutics 的新股份，价值约 147,000 美元。CIBC Bancorp USA Inc.在第三季度购买了 Compass Therapeutics 的新股份，价值约 37,000 美元。最后，Vivo Capital LLC 在第三季度将其在 Compass Therapeutics 的持股增加了 57.9%。Vivo Capital LLC 现在拥有 9,545,466 股该公司的股票，价值 33,409,000 美元，此前在上个季度又购买了 3,502,000 股。对冲基金和其他机构投资者持有该公司 68.43% 的股票。</p>
<h2>Compass Therapeutics 价格表现</h2>
<p>CMPX 股票周二开盘价为 6.19 美元。Compass Therapeutics 的 1 年最低价为 1.33 美元，1 年最高价为 6.40 美元。该公司的市值为 11 亿美元，市盈率为-13.76，贝塔值为 1.45。该公司的 50 日移动平均线为 5.34 美元，200 日移动平均线为 4.18 美元。</p>
<p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.08 美元，超出市场共识预期的-0.14 美元，超出幅度为 0.06 美元。卖方分析师预计 Compass Therapeutics 在当前财政年度将发布-0.36 美元的每股收益。</p>
<h2>关于 Compass Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台来识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
<p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Compass Therapeutics</li>
<li>家族信托如何帮助保护您的财富</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>一项价值数万亿美元的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>行政命令 14330：特朗普最大的一次</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
<p>在您考虑 Compass Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Compass Therapeutics 并不在名单上。</p>
<p>虽然 Compass Therapeutics 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPX

<p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX）获得了十五位分析师的 “适度买入” 共识评级。其中一位分析师给予卖出评级，十三位给予买入评级，另一位给予强烈买入评级。12 个月的平均目标价为 12.23 美元。最近的报道包括 Lifesci Capital 给予的 “跑赢大盘” 评级，目标价为 10 美元。对冲基金持有该股票的 68.43%，开盘价为 6.19 美元，1 年最低价为 1.33 美元，最高价为 6.40 美元。该公司报告上个季度每股收益为（0.08 美元），超出预期</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the fifteen analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $12.2308.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX - 获取免费报告）在目前覆盖该公司的十五位分析师中被评为 “适度买入”，Marketbeat.com 报道。一位投资分析师给予该股票卖出评级，十三位给予买入评级，一位给予强烈买入评级。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价为 12.2308 美元。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师仍然看好的前三家高动量公司</li>
</ul>
</div><p>A number of brokerages recently commented on CMPX. Lifesci Capital assumed coverage on Compass Therapeutics in a report on Monday, October 6th. They set an &#34;outperform&#34; rating and a $10.00 target price for the company. William Blair started coverage on Compass Therapeutics in a research report on Monday, January 5th. They set an &#34;outperform&#34; rating on the stock. Compass Point set a $10.00 target price on Compass Therapeutics in a report on Monday, October 6th. Citizens Jmp began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a &#34;market outperform&#34; rating and a $10.00 price target on the stock. Finally, JMP Securities set a $10.00 price objective on Compass Therapeutics in a research report on Wednesday, December 3rd.</p>
<div class="lb-trans"><p>多家券商最近对 CMPX 发表了评论。Lifesci Capital 在 10 月 6 日的报告中开始覆盖 Compass Therapeutics。他们给予该公司 “跑赢大盘” 的评级，并设定了 10.00 美元的目标价。William Blair 在 1 月 5 日的研究报告中开始覆盖 Compass Therapeutics。他们对该股票给予了 “跑赢大盘” 的评级。Compass Point 在 10 月 6 日的报告中对 Compass Therapeutics 设定了 10.00 美元的目标价。Citizens Jmp 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics。他们给予该股票 “市场跑赢大盘” 的评级，并设定了 10.00 美元的目标价。最后，JMP Securities 在 12 月 3 日的研究报告中对 Compass Therapeutics 设定了 10.00 美元的目标。</p>
</div><p><strong>Read Our Latest Research Report on Compass Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Compass Therapeutics 的最新研究报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new stake in Compass Therapeutics during the fourth quarter worth approximately $32,000. Tema Etfs LLC acquired a new stake in Compass Therapeutics during the fourth quarter worth approximately $538,000. Avanza Fonder AB purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth approximately $147,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Compass Therapeutics during the 3rd quarter worth approximately $37,000. Finally, Vivo Capital LLC boosted its holdings in shares of Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Flagship Harbor Advisors LLC 在第四季度购买了 Compass Therapeutics 的新股份，价值约 32,000 美元。Tema Etfs LLC 在第四季度收购了 Compass Therapeutics 的新股份，价值约 538,000 美元。Avanza Fonder AB 在第四季度购买了 Compass Therapeutics 的新股份，价值约 147,000 美元。CIBC Bancorp USA Inc.在第三季度购买了 Compass Therapeutics 的新股份，价值约 37,000 美元。最后，Vivo Capital LLC 在第三季度将其在 Compass Therapeutics 的持股增加了 57.9%。Vivo Capital LLC 现在拥有 9,545,466 股该公司的股票，价值 33,409,000 美元，此前在上个季度又购买了 3,502,000 股。对冲基金和其他机构投资者持有该公司 68.43% 的股票。</p>
</div><h2>Compass Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Compass Therapeutics 价格表现</h2>
</div><p>Shares of CMPX stock opened at $6.19 on Tuesday. Compass Therapeutics has a 1-year low of $1.33 and a 1-year high of $6.40. The firm has a market cap of $1.10 billion, a PE ratio of -13.76 and a beta of 1.45. The company has a 50-day moving average of $5.34 and a two-hundred day moving average of $4.18.</p>
<div class="lb-trans"><p>CMPX 股票周二开盘价为 6.19 美元。Compass Therapeutics 的 1 年最低价为 1.33 美元，1 年最高价为 6.40 美元。该公司的市值为 11 亿美元，市盈率为-13.76，贝塔值为 1.45。该公司的 50 日移动平均线为 5.34 美元，200 日移动平均线为 4.18 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. Sell-side analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.08 美元，超出市场共识预期的-0.14 美元，超出幅度为 0.06 美元。卖方分析师预计 Compass Therapeutics 在当前财政年度将发布-0.36 美元的每股收益。</p>
</div><h2>About Compass Therapeutics</h2>
<div class="lb-trans"><h2>关于 Compass Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台来识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Compass Therapeutics</li>
<li>家族信托如何帮助保护您的财富</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>一项价值数万亿美元的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>行政命令 14330：特朗普最大的一次</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CMPX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Compass Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Compass Therapeutics 并不在名单上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Therapeutics 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Therapeutics, Inc. (NASDAQ:CMPX) 获得分析师一致评级为 “适度买入”